Top Clinical Trials companies in Cayman Islands by Revenue Per Share
This ranking features the top 2 Clinical Trials companies in Cayman Islands ranked by Revenue Per Share, averaging a Revenue Per Share of USD 0.69, for January 15, 2025.
Cayman Islands
Clinical Trials
Revenue Per Share
# |
Name |
Revenue Per Share |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
|---|---|---|---|---|---|---|---|
| 1 |
USD 1.04
|
Dec. 31, 2023 | USD 8.53 | -0.47% |
|
Cayman Islands |
|
| 2 |
USD 0.35
|
Dec. 31, 2023 | USD 2.01 | 1.52% |
|
Cayman Islands |
Frequently Asked Questions
-
Which Clinical Trials company in Cayman Islands has the highest Revenue Per Share ?
The Clinical Trials company in Cayman Islands with the highest Revenue Per Share is Theravance Biopharma, Inc. (NasdaqGM: TBPH) at USD 1.04.
-
Which Clinical Trials company in Cayman Islands has the lowest Revenue Per Share ?
The Clinical Trials company in Cayman Islands with the lowest Revenue Per Share is Adlai Nortye Ltd. American Depositary Shares (NasdaqGM: ANL) at USD 0.35.
-
What are the top 10 Clinical Trials companies in Cayman Islands by Revenue Per Share ?
The top 10 Clinical Trials companies in Cayman Islands by Revenue Per Share are Theravance Biopharma, Inc. and Adlai Nortye Ltd. American Depositary Shares.
-
What are the bottom 10 Clinical Trials companies in Cayman Islands by Revenue Per Share ?
The bottom 10 Clinical Trials companies in Cayman Islands by Revenue Per Share are Adlai Nortye Ltd. American Depositary Shares and Theravance Biopharma, Inc..